Lori Pigg
Psychiatry · Fayetteville, TNNPI 1003224007
Payments from drug & device makers
Across 180 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$790
- Teva Pharmaceuticals USA, Inc.$734
- Otsuka America Pharmaceutical, Inc.$429
- Alkermes, Inc.$424
- Neurocrine Biosciences, Inc.$297
- E.r. Squibb & Sons, L.L.C.$272
- plus $543 from 6 others
What the payments were for
- Food & beverage$3,36897%
- Education$1193%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $790 |
| Teva Pharmaceuticals USA, Inc. | 35 | $734 |
| Otsuka America Pharmaceutical, Inc. | 21 | $429 |
| Alkermes, Inc. | 22 | $424 |
| Neurocrine Biosciences, Inc. | 14 | $297 |
| E.r. Squibb & Sons, L.L.C. | 14 | $272 |
| AbbVie | 13 | $244 |
| Axsome Therapeutics, Inc. | 3 | $163 |
| Johnson & Johnson | 3 | $77 |
| Lundbeck LLC | 1 | $22 |
| Luye Pharma (USA) Ltd. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$125
How this compares
$3,487 in reported general payments places this provider in the 80th percentile of 503 psychiatry providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 82 | $119,083 |
| CaplytaLumateperone Tosylate | 17 | $26,256 |
| AristadaAripiprazole Lauroxil | 11 | $23,872 |
| Asenapine Maleate | 13 | $5,561 |
| Aripiprazole | 35 | $1,804 |
| Ziprasidone Hcl | 11 | $1,584 |
| Buspirone Hcl | 74 | $1,564 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 14 | $1,511 |
| Duloxetine Hcl | 47 | $942 |
| Lamotrigine | 86 | $880 |
| Ramelteon | 13 | $848 |
| Prazosin Hcl | 37 | $769 |
| Oxcarbazepine | 16 | $752 |
| Risperidone OdtRisperidone | 11 | $683 |
| Bupropion XlBupropion Hcl | 13 | $629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $244 | $119,08382 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $790 | $26,25617 claims |
| Alkermes, Inc.Aristada | $424 | $23,87211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 503 psychiatry providers in Tennessee.
Other psychiatry in Fayetteville
- Rakesh AminNashville$3M
- Brian BonfardinJohnson City$2.6M
- Paul NewhouseNashville$1.4M
- John FenleyJohnson City$1.4M
- Anita VarmaMemphis$1.3M
- Patricia AndrewsNashville$748K
- David SnowMaryville$605K
- Jonathan BeckerBrentwood$261K
- Robert FallisNashville$241K
- James HartFranklin$226K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.